Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

about

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

Item

http://www.wikidata.org/entity/Q42488887

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@en

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@nl

type

Item

label

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@en

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@nl

prefLabel

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@en

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@nl

P1476

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream

@en

P2093

Joshua A Zeichner

http://www.w3.org/2001/XMLSchema#string

Miriam B Birge

http://www.w3.org/2001/XMLSchema#string

Rita V Patel

http://www.w3.org/2001/XMLSchema#string

P2860

Imiquimod applied topically: a novel immune response modifier and new class of drug

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles.

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.

Basal-cell carcinoma.

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.

Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.

Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic.

P304

39-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21607193

http://www.w3.org/2001/XMLSchema#string

P932

3100110

http://www.w3.org/2001/XMLSchema#string